Trevi Therapeutics, Inc. (TRVI)

Market Cap	311.31M
Revenue (ttm)	n/a
Net Income (ttm)	-44.32M
Shares Out	76.87M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,741,528
Open	4.060
Previous Close	4.150
Day's Range	4.050 - 4.390
52-Week Range	1.270 - 4.675
Beta	0.96
Analysts	Strong Buy
Price Target	9.31 (+129.88%)
Earnings Date	Nov 6, 2024

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Ref...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 7, 2019
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: TRVI
• Website: https://www.trevitherapeutics.com

Analyst Forecast

According to 8 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is $9.31, which is an increase of 129.88% from the latest price.

Price Target

$9.31

(129.88% upside)

Analyst Consensus: Strong Buy